Drugs in Dev.
Oncology
Undisclosed
Denmark 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epcoritamab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program for Epcoritamab
Details : Epcoritamab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Epcoritamab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Novo Seeds
Deal Size : $62.2 million
Deal Type : Series A Financing
Details : The new financing, which is the largest Series A financing for a Danish biotech company to develop Antibody drug conjugate, will be used to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting uPARAP/Endo1...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Novo Seeds
Deal Size : $62.2 million
Deal Type : Series A Financing
